Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

Status Completed

Clinical Trial Summary

Primary Objective: To determine the dose-response relationship for SAR442168 to reduce the number of new active brain lesions. Secondary Objectives: - To evaluate efficacy of SAR442168 on disease activity as assessed by imaging measures. - To evaluate the safety and tolerability of SAR442168.

Clinical Trial Description

The total study duration was 24 weeks which included a screening period of 4 weeks, a treatment period of 16 weeks, and a follow-up period of up to 4 weeks. Participants who completed the Week 16 visit were proposed to be enrolled in a long-term extension safety and efficacy study to assess safety, tolerability and efficacy of SAR442168. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03889639
Study type	Interventional
Source	Sanofi
Contact
Status	Completed
Phase	Phase 2
Start date	March 29, 2019
Completion date	January 2, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04121065` - Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)
Active, not recruiting	`NCT03996291` - Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis	Phase 2
Recruiting	`NCT04510220` - 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis	Phase 3
Terminated	`NCT02241785` - Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies	Phase 4
Completed	`NCT02792218` - Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis	Phase 3
Completed	`NCT01412333` - A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis	Phase 3
Completed	`NCT03257358` - A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod	Phase 4
Completed	`NCT01628393` - Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients	Phase 2/Phase 3
Completed	`NCT04626921` - A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis	Phase 2/Phase 3
Withdrawn	`NCT02234869` - Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy	Phase 4
Withdrawn	`NCT05077956` - Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis
Active, not recruiting	`NCT04486716` - A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis	Phase 3
Recruiting	`NCT04121403` - Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)	Phase 3
Recruiting	`NCT05809986` - Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
Terminated	`NCT00988052` - A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course	Phase 3
Active, not recruiting	`NCT05232825` - A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis	Phase 3
Terminated	`NCT01047319` - A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis	Phase 3
Completed	`NCT04847596` - A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
Completed	`NCT01127750` - Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients	Phase 3
Completed	`NCT01006941` - Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study	Phase 2